"There isnt a directly labeled warning for that, so we havent seen any drug evidence of that, but it is a concern for oral medications, any of them, including birth control." Other concerns about this unexpected trend are being studied by the U.S
Fatty liver disease In 2025, Wegovy received an additional FDA approval for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) a serious form of fatty liver disease driven by insulin resistance
However, due to species-specific differences in lactation physiology, the clinical relevance of these data is not clear (see Data)
Basudkar V, Gujrati G, Ajgaonkar S, Gandhi M, Mehta D, Nair S (2024) Emerging vistas for the nutraceutical Withania somnifera in inflammaging
Semaglutide hasnt just helped me lose weight